Up to $3 billion in pharmaceuticals currently used in the United States (U.S.) depend on Canadian manufacturing, according to new research findings from the University of Toronto. Applying 25 per cent trade tariffs to these pharmaceuticals could add $750 million in cost to the U.S. market and has the potential to significantly disrupt drug supply over the long term. The analysis, published today in JAMA, focused on drugs with final production in Canada, a subset of the overall $6.75 billion in pharmaceuticals exported from Canada to the U.S. This accounts for more than 400 different ready-for-use medications, of which 28 have no alternative supplier. “The proposed tariffs could affect a wide range of medications, from antibiotics to mental health treatments,” said Mina Tadrous, lead author and assistant professor, Leslie Dan Faculty of Pharmacy, University of Toronto. “Straining this supply chain could trigger drug shortages… 

Die Komorbidität von Essattacken und übermäßigem Alkoholkonsum ist weit verbreitet und erhöht das Risiko für andere neuropsychiatrische und körperliche Erkrankungen. Die Mechanismen, die diese Formen des Rauschkonsums verbinden, sind jedoch unklar. Um den Zusammenhang zwischen Essattacken und übermäßigem Alkoholkonsum zu untersuchen, entwickelten Karen Szumlinski von der University of California in Santa Barbara und ihre Kollegen eine Methode, um die Komorbidität der Krankheit bei Mäusen zu modellieren. Wie in ihrem JNeurosci- Artikel berichtet, führte dieses Mausmodell zu der Entdeckung, dass weibliche Tiere mit einer Vorgeschichte von Essattacken schneller mit übermäßigem Alkoholkonsum beginnen als männliche Tiere. Die Forscher fanden auch heraus, dass weibliche Tiere erhöhte Werte eines Proteins namens Phosphodiesterase 4B (PDE4B) aufwiesen, das zuvor mit komorbider Alkoholkonsumstörung und Essstörungen in Verbindung gebracht wurde. Die Hemmung des Proteins verhinderte das gleichzeitige Auftreten von Essattacken bei Mäusen beiderlei Geschlechts. Laut den Autoren unterstützt diese Studie… 

EDGNEX Data Centers by DAMAC, the digital infrastructure platform of the Dubai-headquartered DAMAC Group, has confirmed the acquisition of Finland-founded data center company, Hyperco. Aligned with its vision to deliver next-generation, sustainable digital infrastructure globally, the move underscores the Group’s commitment to strengthening its presence in the European market and contributing to the region’s evolving data center landscape, creating new jobs and promoting economic development. Hyperco’s operations are focused on Finland and Sweden, leveraging the Nordic region’s sustainable energy resources, mature digital ecosystems, and high connectivity. All three Hyperco founders, together with the team, will continue to steer the company forward during the next growth phase. Hussain Sajwani, Founder of DAMAC Group said: „This acquisition aligns with our vision to develop strong partnerships, invest, and build scalable, world-class digital infrastructure. Hyperco brings a great team, deep market expertise, and a shared commitment… 

AZmed, one of the leading AI companies in medical imaging, today announced that it has received two new U.S. Food and Drug Administration (FDA) clearances for its AI tool AZchest. The clearances include applications intended to assist radiologists in the interpretation and detection of chest X-rays for lung nodules and triage capabilities for pneumothorax and pleural effusion. A standalone study on chest X-rays showed that AZchest has extremely high sensitivity in detecting lung nodules, at 88.47%, associated with a high specificity of 82.94%. In a controlled multi-reader multi-case trial, experienced radiologists interpreted a standardized set of chest X-rays both with and without the assistance of AZchest. When aided by AZchest, the sensitivity increased by 10%, reaching 89.35%. The AUC also increased by 5%. Regarding the triaging of pneumothorax and pleural effusion, the algorithm also confirmed its high detection performance. The…